Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

December 13, 2019

Bemcentinib-Keytruda Combo Effective in Some Advanced NSCLC Patients with Poor Prognosis

News

Combining bemcentinib with Keytruda (pembrolizumab) is effective and delays disease progression in people with previously treated advanced non-small cell lung cancer (NSCLC), particularly in those with AXL-positive tumors. Those updated results from a Phase 2 ... Read more

November 11, 2019

2 Imfinzi Combos Delay Cancer Progression in Metastatic NSCLC, Interim Phase 3 Data Show

News

Adding Imfinzi (durvalumab) — alone or in combination with tremelimumab — to standard first-line chemotherapy significantly delayed disease progression or death in people with metastatic non-small cell lung cancer (NSCLC), compared ... Read more

October 9, 2019October 9, 2019

Keytruda Approved in China as First-Line Lung Cancer Treatment

News

The Chinese National Medical Products Administration (NMPA) has approved Keytruda (pembrolizumab) as a first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC), Merck (known as MSD outside the U.S. and Canada) ... Read more

October 8, 2019

Opdivo-Yervoy Combo Prolongs Survival in Patients with Advanced NSCLC, Phase 3 Study Shows

News

A combination of Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) induces significant survival benefits in people with advanced non-small cell lung cancer (NSCLC), compared to chemotherapy alone, data from a ... Read more

August 27, 2019September 18, 2019

EU Committee Recommends Orphan Drug Status for Ziopharm’s IL-12 Gene Therapy for Glioblastoma

News

A European Medicines Agency (EMA) committee has recommended orphan drug designation for Ziopharm Oncology‘s interleukin (IL)-12 gene therapy — known as the Controlled IL-12 platform — for the treatment of glioblastoma, ... Read more

October 31, 2018October 31, 2018

Immunotherapy Particularly Effective Against Aggressive Hereditary Melanoma, Study Reports

News

Patients with hereditary melanoma associated with mutations in the CDKN2A gene respond well to immunotherapy, possible due to an increased mutational load in these tumors, a study suggests. The ... Read more

October 24, 2018

Keytruda Improves Survival in Patients with Relapsed or Metastatic Head, Neck Cancer, Interim Data Show

News

First-line treatment with Keytruda (pembrolizumab) — alone or in combination with standard chemotherapy — significantly prolongs survival of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), ... Read more

August 17, 2018August 17, 2018

Cancer Cells Can Flood Bloodstream with Protein ‘Warriors’ Against Immune Response, Study Finds

News

Cancer cells release into the bloodstream small vesicles armed with PD-1 ligand (PD-L1) — a protein that suppresses the activation of cancer-fighting immune cells — so as to mute ... Read more

June 26, 2018June 26, 2018

Gene Editing of Healthy Cells Improves CAR T-cell Therapy for AML, Preclinical Study Shows

News

Genetic modification of healthy blood stem cells prevents off-target effects of chimeric antigen receptor (CAR) T-cell therapy for treating acute myeloid leukemia (AML), a recent preclinical study shows. The study, ... Read more

April 17, 2018

Immunotherapy Combo Boosts Survival in Mouse Models of Mesothelioma, Study Finds

News

A combination of two immunotherapies — VIC-008 and Mozobil (plerixafor, or AMD3100) — suppresses mesothelioma growth and prolongs survival, suggesting a potential therapy for this type of cancer, a ... Read more

Pin It on Pinterest